Transition Therapeutics Inc is a product-focused biopharmaceutical company. The Company's principal business activity is the researching and developing of therapeutic agents. The Company is developing therapeutics for central nervous system (CNS) and metabolic disease indications. The Company's technologies are focused on the treatment of agitation and aggression in Alzheimer's disease and diabetes.
Read More…
Industry, Sector and Symbol
Industry N/A
Sub-IndustryN/A
SectorN/A
Phone+1-416-2607770
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable
Transition Therapeutics (NASDAQ:TTHI) Frequently Asked Questions
What is Transition Therapeutics' stock symbol?
Transition Therapeutics trades on the NASDAQ under the ticker symbol "TTHI."
Has Transition Therapeutics been receiving favorable news coverage?
Media headlines about TTHI stock have trended very negative recently, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Transition Therapeutics earned a media sentiment score of -3.2 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the near term. View News Stories for Transition Therapeutics.
What other stocks do shareholders of Transition Therapeutics own?
What is Transition Therapeutics' official website?
How can I contact Transition Therapeutics?
Transition Therapeutics' mailing address is 101 College St Suite 220, TORONTO, ON M5G 1L7, Canada. The biopharmaceutical company can be reached via phone at +1-416-2607770.
MarketBeat Community Rating for Transition Therapeutics (NASDAQ TTHI)
MarketBeat's community ratings are surveys of what our community members think about Transition Therapeutics and other stocks. Vote "Outperform" if you believe TTHI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TTHI will underperform the S&P 500 over the long term. You may vote once every thirty days.
